Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline-Reference-Cited by-同舟云学术

Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline

Published:2024-01-15 Issue:2 Volume:209 Page:137-152
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Raghu Ganesh^ORCID,Montesi Sydney B.^ORCID,Silver Richard M.^ORCID,Hossain Tanzib^ORCID,Macrea Madalina^ORCID,Herman Derrick^ORCID,Barnes Hayley^ORCID,Adegunsoye Ayodeji^ORCID,Azuma Arata^ORCID,Chung Lorinda^ORCID,Gardner Gregory C.^ORCID,Highland Kristin B.^ORCID,Hudson Marie,Kaner Robert J.^ORCID,Kolb Martin^ORCID,Scholand Mary Beth^ORCID,Steen Virginia^ORCID,Thomson Carey C.,Volkmann Elizabeth R.^ORCID,Wigley Fredrick M.,Burlile Dee,Kemper Karen A.^ORCID,Knight Shandra L.^ORCID,Ghazipura Marya^ORCID

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202306-1113ST

Reference49 articles.

1. Preliminary criteria for the classification of systemic sclerosis (scleroderma)

2. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

3. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

4. Cyclophosphamide versus Placebo in Scleroderma Lung Disease

5. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary Manifestations of IBD: Case Report and Review of the Literature;Journal of Clinical Medicine;2024-09-12

2. The 2024 British Society for Rheumatology guideline for management of systemic sclerosis;Rheumatology;2024-09-11

3. Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease;RMD Open;2024-09

4. Use of artificial intelligence algorithms to analyse systemic sclerosis-interstitial lung disease imaging features;Rheumatology International;2024-08-29

5. Real-World Clinical Profile and Safety of Nintedanib in Systemic Sclerosis-Associated Interstitial Lung Disease: A Subgroup Analysis of Interstitial Lung Disease Data From an Interstitial Lung Disease (ILD) Specialty Clinic in India;Cureus;2024-07-28